Neoadjuvant Immunotherapy in Genitourinary Tumors
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 20 October 2024 | Viewed by 326
Special Issue Editors
Interests: urology; uro-oncology; andrology; kidney stones; urolithiasis; incontinence; CEUS; contrast-enhanced ultrasound; kidney cancer; bladder cancer; prostate cancer; penile cancer; reflux
2. Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy
Interests: uro-oncology
2. Department of Medical Biotechnology, University of Siena, 53100 Siena, Italy
Interests: cancer; diabetes; cardiovascular disease
Special Issue Information
Dear Colleagues,
Genitourinary (GU) malignancies affect many people worldwide, with millions of new cases diagnosed annually. In recent decades, our understanding of cancer and its pathophysiology has evolved. It has been well established that cancer cells have developed multiple mechanisms to avoid the immune system.
The use of immunotherapy in the preoperative or neoadjuvant setting is supported by preclinical studies showing that stronger and broader immune responses can be generated when immunotherapy is administered with the primary tumor and/or regional lymph nodes intact. By interfering with pathways in the tumor microenvironment, immune checkpoint inhibitors (ICIs) allow the immune system to “ramp up” and effectively target malignant cells.
This Special Issue delves into the role of immunotherapy in the treatment of GU malignancies, specifically urothelial, renal, prostate, and other rarer tumors. The goal is to enhance “precision therapy” evidence to increase overall survival and progression-free survival.
Dr. Antonio Tufano
Dr. Nadia Cordua
Prof. Dr. Antonio Giordano
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapy
- immune checkpoint inhibitor
- bladder cancer
- urothelial cancer
- kidney cancer
- renal cell carcinoma
- prostate cancer
- testicular cancer
- penile cancer
- adrenocortical carcinoma
